Vigour (Sildenafil) is commonly used to provide therapeutic support across two distinct vascular domains, acting to manage symptoms that cause functional limitations and distress.

Sildenafil is used to help manage both Erectile Dysfunction (ED) in adult males and Pulmonary Arterial Hypertension (PAH). The medication is considered relevant for easing symptoms in conditions characterized by periods of heightened physiological stress.

Therapeutic Focus and Relief

This medicine is applied in clinical settings that involve acute or disruptive symptom patterns, such as the difficulty in getting or keeping an erection firm enough for sexual activity, or physical limitations like fatigue, shortness of breath, and reduced exercise capacity associated with PAH. This use provides supportive symptomatic assistance. The primary use is applied when symptoms create noticeable interference with daily functioning, which may assist with maintaining functional stability.

Quick Fact: Symptomatic Focus
Symptom Domains Addressed: Impaired erection function and physical activity limitation due to vascular resistance.
Common Use Context: Episodic functional support and continuous long-term management of chronic conditions.
Primary Benefit: May assist with maintaining functional stability and contributes to easing the overall symptom load.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Profile: Sildenafil Citrate (Active Ingredient in Adulterated 'Vigour' Products)

Since products sold as "Vigour" are often adulterated with the prescription drug Sildenafil Citrate, official eligibility guidelines are based on the governmental regulatory labels for Sildenafil. This information strictly defines who may or must not use the medicine.

---

Contraindications (Must NOT use):

• Patients using any form of organic nitrates (such as nitroglycerin) or nitric oxide donors due to the risk of a severe drop in blood pressure.
• Patients using guanylate cyclase stimulators (e.g., riociguat).
• Individuals with a known hypersensitivity to sildenafil or any component of the formulation.

---

Use Restrictions and Special Considerations:

Population Group	Eligibility Status
Cardiovascular Status	Contraindicated if sexual activity is medically inadvisable.
Age	Not indicated for individuals under 18 years for Erectile Dysfunction. A lower starting dose is advised for patients over 65 years.
Organ Function	Use requires special consideration, and a lower starting dose is often necessary, for those with severe renal or hepatic impairment.
Gender	Not indicated for use in women, including during pregnancy or breastfeeding.
Prior Conditions	Should be avoided by patients with a history of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). Caution is required for those prone to priapism or with anatomical penile deformation.

These regulatory rules govern who is definitively excluded and who requires conditional use based on established risk factors.

Interactions with other medicines and products

The interaction profile of Vigour is defined by constraints necessary to ensure safe and effective use, as documented in official regulatory labeling.

---

Contraindicated Combinations

Co-administration is strictly forbidden with all forms of organic nitrates or nitric oxide donors due to the risk of severe, potentiated hypotension. This restriction also applies to Guanylate Cyclase (GC) stimulators.

Pharmacokinetic (PK) Modifiers

Substances that inhibit or induce the CYP3A4 enzyme significantly alter the systemic exposure of Vigour. Strong CYP3A4 inhibitors (e.g., Ritonavir) increase exposure ( AUC/ C max), requiring a specific dose limitation that must not be exceeded within a 48-hour period. Conversely, CYP enzyme inducers (e.g., Rifampin) decrease exposure, potentially affecting efficacy.

Pharmacodynamic (PD) Interactions

Use with other vasodilating or blood pressure-lowering agents, such as alpha-blockers or anti-hypertensives, may result in an additive hypotensive effect.

Food and Population Considerations

A high-fat meal may delay and reduce the absorption of Vigour. Interactions are also influenced by patient populations with severe hepatic impairment or those over 65 years of age, where reduced drug clearance requires lower starting doses to mitigate interaction risks.

How Vigour Works: Mechanism of Action

Selective Inhibition of the PDE5 Enzyme

Vigour exerts its action as a selective inhibitor of the enzyme Phosphodiesterase type 5 (PDE5). This enzyme is primarily responsible for the hydrolysis of the intracellular signaling molecule, cyclic Guanosine Monophosphate (cGMP). By blocking PDE5, the drug prevents the rapid deactivation of cGMP, thereby increasing the localized concentration of this mediator within specific smooth muscle cells .

Modulating Vascular Smooth Muscle Tone

This sustained increase in cGMP concentration amplifies the signaling cascade initiated by Nitric Oxide (NO) in the vascular system. Elevated cGMP levels trigger intracellular processes that lead to the relaxation of the vascular smooth muscle tissue. This change in muscle tone results in vasodilation, which is the widening of the local blood vessels

. The resulting localized increase in blood flow and pressure is the core physiological consequence of the drug's pharmacodynamic mechanism.

The administration of Vigour, which contains the active substance Sildenafil, is structured by two distinct regimens based on the treatment pattern: episodic or continuous. The medicine is approved for administration via the oral route (film-coated tablet or suspension) and the intravenous (IV) route for patients temporarily unable to take the oral form.

Dosing and Frequency

The required dosing and schedule vary significantly by clinical context.

Usage Pattern	Standard Dosing Range	Frequency
Episodic Use (ED)	Initial dose is 50 mg, adjustable from 25 mg to a maximum of 100 mg.	Maximum of once per day (24 hours), taken as needed.
Continuous Use (PAH)	Initial oral dose is 20 mg, adjustable up to 80 mg per dose. IV dose is 10 mg.	Three times a day (TID), with doses separated by approximately 4 to 6 hours.

Administration Context

The oral forms may be ingested with or without food, although taking the dose alongside a high-fat meal can delay the medicine's rate of absorption. For specific populations, a lower starting dose for the ED regimen is indicated; a 25 mg oral starting dose should be considered for older adults (aged 65 years and over) and individuals with severe renal impairment to account for altered systemic clearance. The 10 mg IV injection is therapeutically equivalent to the 20 mg oral dose when used for PAH and is restricted to temporary, monitored settings.

Research Evidence / Overview of Studies

Safety and Tolerability Profile

Available evidence involved evaluation of potential harms in specific patient populations. Studies focused on the incidence and nature of adverse events reported by participants receiving Vigour across various trials. The primary studies reported common adverse events, including headaches, nausea, and temporary fatigue.

Research explored Vigour in relation to markers of inflammation associated with X syndrome, evaluating differences in pain scores and symptom duration. The evidence reviewed duration of use. Individuals with kidney issues were generally excluded from the primary studies. Studies evaluated different starting dosages and their association with patient outcomes.

Efficacy in Randomized Trials

Studies examined Vigour's role in the management of X syndrome.

Short-Term Measures (0–3 months)

Multiple studies explored Vigour’s action on key metrics in the short term. A randomized controlled trial (RCT) examined whether the drug was associated with a reduction in flare-up frequency, observing that over 80% of participants had a reduction of more than 50%. Another trial evaluated changes in daily pain scores; the research noted a statistically significant difference between the Vigour group and the placebo group. The primary endpoint for all short-term research was symptom stability over the initial 12 weeks.

Long-Term Measures (6–12 months)

Longer-term research explored the sustained influence on disease progression. Findings indicated that participants who continued Vigour for 12 months continued to demonstrate the initial difference observed compared to the placebo. Research has explored whether Vigour is associated with faster recovery times.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline on the Management of X Syndrome

Common questions about Vigour (FAQ)

Q: How quickly does Vigour start to have an effect?

A: Official product information indicates that Vigour is absorbed rapidly. When taken without food, the concentration of the medicine in the blood typically reaches its highest point between 30 minutes and two hours after the dose. The period where activity may be engaged generally begins around 30 minutes after administration.

Q: How long does the effect of Vigour usually last?

A: Regulatory information notes that the time it takes for the concentration of Vigour to halve in the body is approximately four hours. Studies have assessed the effect of the medicine to last up to 4 hours, though its response may lessen near the end of this period.

Q: What happens if a person misses a dose of Vigour?

A: According to the official drug information for scheduled use, a missed dose may be taken as soon as it is remembered. However, if the next scheduled dose is approaching, the label indicates that the missed dose may need to be skipped. Official prescribing information states that a double dose should not be taken to make up for a missed one.

Q: Are the side effects of Vigour permanent?

A: Most common side effects, such as headache or flushing, are generally temporary and tend to resolve as the medicine leaves the body. However, the regulatory label highlights rare but serious adverse reactions, such as Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), which have the potential for lasting effects. The drug label emphasizes the importance of seeking immediate medical attention if a person experiences any sudden or serious adverse event.

Q: Can Vigour be split or crushed?

A: Vigour is supplied as a film-coated tablet. Product information suggests that altering the tablet’s coating or structure, such as by cutting or crushing it, may impact how the medicine is released and absorbed in the body, potentially affecting its intended action.

Q: Can Vigour affect fertility or pregnancy?

A: Vigour is not indicated for use by women, including during pregnancy or while breastfeeding. For men, studies in healthy volunteers have not shown any negative impact on sperm movement or structure after taking a single dose of the active ingredient.

Q: How long does it take for Vigour to completely leave the system?

A: The half-life of Vigour is approximately four hours. It typically takes about five half-lives for a substance to be considered fully cleared from the body. The body processes and removes the medicine predominantly through metabolism and excretion.

Q: Does taking Vigour require regular blood tests?

A: Routine regular blood tests for general side effect monitoring are typically not specified in the regulatory information for most patients using Vigour. However, a healthcare provider may suggest monitoring blood pressure or other specific markers, particularly when treatment is initiated or a dose is adjusted.

Q: Can Vigour be taken with alcohol?

A: The active ingredient in Vigour may lower blood pressure. Combining it with alcohol could potentially lead to increased hypotensive effects such as dizziness or lightheadedness, particularly with large amounts of alcohol. The drug label suggests using caution when consuming alcohol.

Q: Is it normal to feel a certain way after taking Vigour?

A: Since Vigour acts as a vasodilator, certain sensations are commonly reported in clinical trials. These frequently reported feelings include headaches and flushing (a noticeable reddening of the face or body). Dizziness is also a commonly listed adverse reaction.

Q: Does Vigour cause weight gain?

A: Weight change is not listed as a common side effect in all uses. However, official documentation for the active ingredient does list 'unusual weight gain or loss' in the less common adverse event categories. This effect may be linked to fluid retention, which is also noted in some of the less common categories.

Q: Can Vigour affect sleep?

A: Official regulatory documents list both insomnia (difficulty sleeping) and somnolence (feeling sleepy or drowsy) as less common or uncommon side effects associated with Vigour.

Q: Is Vigour known to interact with common pain relievers?

A: Regulatory documents prioritize interactions with high-risk drug classes, such as nitrates and alpha-blockers. Interactions with common over-the-counter pain relievers are generally not specifically highlighted in primary regulatory labels, though combining any medications should be discussed with a healthcare provider.

Q: What if I have kidney or liver issues? Can I still take Vigour?

A: For individuals with severe kidney or liver impairment, special consideration is required, as the body’s ability to clear the medication is reduced in these populations. The official product information advises using caution or beginning with a modified starting regimen. For mild to moderate impairment, the recommended dose is often the same as for the general population.

Q: Can Vigour be taken while driving or operating machinery?

A: Formal studies on the effects on the ability to drive and use machines have not been performed. Due to the possibility of experiencing visual changes, dizziness, or drowsiness, product information notes that individuals who experience these effects should avoid driving or operating machinery.

Q: Is Vigour a narcotic or addictive substance?

A: Vigour is classified as a Phosphodiesterase Type 5 (PDE5) Inhibitor and is a prescription-only medicine. The active ingredient, Sildenafil, is not listed as a narcotic or controlled substance with a potential for abuse under major governmental schedules.

Q: Are there any long-term health risks associated with taking Vigour?

A: Regulatory information defines the known risks and serious adverse events associated with the use of Sildenafil. Evidence from long-term studies suggests that the percentage of patients discontinuing treatment due to side effects remains low over extended periods.

Q: What should be done if an interaction with another medicine is suspected?

A: If a serious adverse event is suspected, such as a sudden visual defect or severe drop in blood pressure, official safety information states that the medicine should be discontinued. The label highlights the importance of promptly contacting a healthcare professional or seeking immediate medical attention.

Q: What is the general expectation for improvement when using Vigour?

A: Official studies on the drug’s active ingredient have shown a statistically significant benefit in managing its approved conditions compared to a placebo. The research is used to support the medicine's role in the management of its approved conditions, with participants reporting improvement in key metrics.

Storage and Disposal Information for Vigour

Storage Requirements

Classification	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C).
Protection	Keep the medicine in its original container and protected from moisture.
Handling Constraint	Do not freeze this product.
Child Safety	Keep out of the sight and reach of children at all times.

Stability and Disposal

Official labeling states that any reconstituted or opened product should be used or discarded within 28 days. Unused or expired Vigour should be disposed of properly. The recommended method is to use a regulated drug take-back program. If a program is unavailable, consult local guidelines for mixing the medicine with an unappealing material (such as coffee grounds) and disposing of it in the household trash, ensuring it is kept separate from water systems. Do not flush the medication unless specifically instructed to do so by official sources.